Skip to Content
Merck
  • Comparison of electrospun and extruded Soluplus®-based solid dosage forms of improved dissolution.

Comparison of electrospun and extruded Soluplus®-based solid dosage forms of improved dissolution.

Journal of pharmaceutical sciences (2011-09-16)
Zsombor K Nagy, Attila Balogh, Balázs Vajna, Attila Farkas, Gergo Patyi, Aron Kramarics, György Marosi
ABSTRACT

Electrospinning (ES) and extrusion of a poorly water-soluble active pharmaceutical ingredient were used to improve its dissolution, which is a major challenge in the field of pharmaceutical technology. Spironolactone was applied as model drug and recently developed polyvinyl caprolactame-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®) was used as carrier matrix and solubilizer. ES of the polymer matrix from ethanol solution was optimized at first without spironolactone and then the cosolution of the drug and the carrier was used for forming electrospun fibers. It resulted in real solid solution due to its very efficient amorphization effect. On the contrary, a low amount of crystalline spironolactone appeared in the extrudates according to Raman microscopy, X-ray diffraction (XRD), scanning electron microscopy (SEM) and energy-dispersive spectrometry (EDS). Raman microspectrometry had the lowest detection limit of spironolactone crystals compared with XRD and differential scanning calorimetry. Both ES and extrusion techniques resulted in significantly improved dissolution. Electrospun ultrafine fibers increased the dissolution more effectively, owing to the formed solid solution and huge surface. The developed continuous technologies demonstrate great potential to tackle the challenge of inadequate dissolution of poorly water-soluble drugs in several cases.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Poly(vinyl acetate), average Mw ~500,000 by GPC
Sigma-Aldrich
Poly(vinyl acetate), average Mw ~100,000 by GPC, beads
Sigma-Aldrich
Kollicoat® SR 30 D, 28.5-31.5% solids basis
Poly(vinyl acetate) dispersion 30 per cent, European Pharmacopoeia (EP) Reference Standard